SPY329.51+2.85 0.87%
DIA266.22+0.74 0.28%
IXIC11,163.39+158.52 1.44%

Morgan Stanley Maintains Overweight on ADC Therapeutics, Lowers Price Target to $52

Morgan Stanley maintains ADC Therapeutics (NYSE:ADCT) with a Overweight and lowers the price target from $53 to $52.

· 10/13/2020 08:13
Morgan Stanley maintains ADC Therapeutics (NYSE:ADCT) with a Overweight and lowers the price target from $53 to $52.